Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.
This site will remain live until Q4 2024 as we transition content to our new site.
May 28, 2021
PHILADELPHIA, May 28, 2021
SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced it has been named 2021 Emerging Company of the Year by Life Sciences Pennsylvania.
“SwanBio is humbled to receive this award and is grateful every day to be part of a dynamic life sciences community with so many deserving nominees,” said Tom Anderson, Chief Executive Officer of SwanBio. “We’re extremely proud of the company and culture we’re building, but most importantly, the scientific innovation we plan to bring forward, fueled by a personal commitment to develop treatments to serve the patients and families living with debilitating neurological disorders. For us, our mission is personal.”
The annual award recognizes a Pennsylvania-based company or organization of 100 employees or fewer that has experienced significant growth and/or achievement, while contributing positively to its community and the overall life sciences business climate of the Commonwealth. The Emerging Company of the Year Award is evaluated based on fundraising/revenue growth, business plan performance, product innovation, community impact, and entrepreneurship & leadership.
